Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (D²EFT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03017872
Recruitment Status : Recruiting
First Posted : January 11, 2017
Last Update Posted : January 12, 2018
National Health and Medical Research Council, Australia
ViiV Healthcare
Janssen Pharmaceutica
Information provided by (Responsible Party):
Kirby Institute

Brief Summary:
D²EFT is a randomised, open-label study in HIV-1 infected patients failing first-line antiretroviral therapy (ART). The study compares a novel regimen of second-line ART (dolutegravir and darunavir pharmaco-enhanced with ritonavir) with the WHO recommended regimen of 2(t)NRTIs plus a ritonavir-boosted PI (Standard of Care (SOC)). 610 participants from 10 predominantly low-middle income countries will be followed for 96 weeks with the primary endpoint at week 48. The design is based on the hypothesis that the new regimen will be non-inferior to SOC in terms of virologic control while being easier to take, economically viable and affording simplification of treatment programs.

Condition or disease Intervention/treatment Phase
HIV Infections Drug: N(t)RTIs Drug: Dolutegravir Drug: Darunavir Drug: Ritonavir Phase 4

Detailed Description:

Consenting participants will be screened and within 45 days randomly allocated to receive either dolutegravir and darunavir/ritonavir or the SOC regimen. Participants will be seen four weeks after their randomisation (week 0) visit and then at weeks 24, 48 and 96. Consenting participants will have storage samples collected and cryopreserved at their week 0, 48 & 96 visits. This repository will be used in future for central baseline resistance testing, pharmacogenomic testing (separate consent required) and has inherent value for later studies of HIV pathogenesis. A 1-time PK sample will be collected at week four for future testing and any participants failing therapy at 24 weeks will have a plasma sample stored for future genotypic resistance testing.

A number of secondary outcomes will be considered in order to compare the performance of the two study treatment regimens. Secondary analyses will focus on virological, immunological, safety, antiretroviral treatment change and medication adherence. A comparison of costs and estimates of cost-effectiveness for the randomised comparison will be a critical component of this study. ART costs will be assessed across study arms. Health-care utilisation will be self-reported and then used to estimate costs. Safety data, viral loads and quality of life data will also be analysed.

The open label nature of the study allows routine care to be undertaken and the use of objective endpoints limit potential bias. The study has well defined and integrated clinical data collection and patient management systems that have been shown to be effective in a wide range of clinical settings.

The choice of N(t)RTIs in the SoC regimen is based on clinical judgement and may be guided by resistance testing if locally available. The NRTIs are not provided via the study. At the end of 96 weeks (completion of the protocol) study drug can be offered to all participants for a further 48 weeks as informed by the 48-week study results and clinical judgement. After 144 weeks study drug will no longer be available and composition of the participant's post-study regimen will be the clinician's decision.'

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 610 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IIIB/IV Randomised Open-label Trial to Compare Dolutegravir + Pharmaco-enhanced Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in Patients With HIV Infection Who Have Failed Recommended First Line Therapy.
Actual Study Start Date : November 1, 2017
Estimated Primary Completion Date : September 30, 2019
Estimated Study Completion Date : December 30, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Standard of Care (SoC) arm
2 x NRTIs + darunavir/ritonavir 800mg/100mg po od
Drug: N(t)RTIs
Choice of N(t)RTI determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.
Other Name: Nucleoside/Nucleotide Reverse Transcription Inhibitors
Drug: Darunavir
800mg tablet by mouth once daily for 96 weeks.
Other Name: Prezista
Drug: Ritonavir
100mg tablet by mouth once daily for 96 weeks.
Other Name: Norvir
Experimental: Dolutegravir arm
Dolutegravir 50mg + darunavir/ritonavir 800mg/100mg po od
Drug: Dolutegravir
50mg tablet by mouth once daily for 96 weeks.
Other Name: Tivicay
Drug: Darunavir
800mg tablet by mouth once daily for 96 weeks.
Other Name: Prezista
Drug: Ritonavir
100mg tablet by mouth once daily for 96 weeks.
Other Name: Norvir

Primary Outcome Measures :
  1. The proportion of participants in each arm whose plasma viral load is <50 copies/mL at 48 weeks by intention to treat. [ Time Frame: At 48 weeks ]

Secondary Outcome Measures :
  1. Proportion with plasma viral load <200 copies/mL [ Time Frame: At 48 and 96 weeks ]
  2. Proportion with plasma viral load <50 copies/mL where those stopping randomised therapy for any reason are classified as plasma viral load >50 copies/mL [ Time Frame: At 48 and 96 weeks ]
  3. Mean change in CD4+ cell count from baseline [ Time Frame: At 48 and 96 weeks ]
  4. Mean/median changes from baseline in fasted lipids (Total cholesterol, LDL-c, HDL-c, and triglycerides) [ Time Frame: At 48 and 96 weeks ]
  5. Total number of participants with any serious adverse events (SAEs), and the cumulative incidence of SAEs [ Time Frame: At 48 and 96 weeks ]
  6. Total number of opportunistic diseases (AIDS events), deaths and serious non-AIDS defining events and the cumulative incidence of these [ Time Frame: At 48 and 96 weeks ]
  7. Adverse events associated with cessation of randomly assigned therapy [ Time Frame: At 48 and 96 weeks ]
  8. Categorisation of neuropsychological adverse events [ Time Frame: At 48 and 96 weeks ]
  9. Proportion who stopped randomised therapy by reason for stopping [ Time Frame: At 48 and 96 weeks ]
  10. Patterns of genotypic HIV resistance associated with virological failure [ Time Frame: At 48 and 96 weeks ]
  11. Adherence assessment using participant 7-day recall self-report questionnaire [ Time Frame: At week 4 ]
  12. Quality of life and anxiety & depression assessed by participant questionnaire [ Time Frame: At 48 and 96 weeks ]
  13. Health care utilisation assessed by participant questionnaire [ Time Frame: At 48 and 96 weeks ]
  14. Cost of care assessment [ Time Frame: At 48 and 96 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. HIV-1 positive by licensed diagnostic test
  2. Aged ≥16 years of age (or minimum age as determined by local regulations or as legal requirements dictate)
  3. Failed first-line non-nucleoside reverse transcriptase inhibitor (NNRTI) + 2N(t)RTI combination therapy according to virological criteria, defined as at least two consecutive (≥7 days apart) pVL results >500 copies/mL after a minimum period of exposure to continuous NNRTI + 2N(t)RTI first-line therapy of 24 weeks (only the second pVL result needs to be within 45 days of randomisation)
  4. Able to provide written informed consent

Exclusion Criteria:

  1. The following laboratory variables:

    1. absolute neutrophil count (ANC) <500 cells/µL
    2. haemoglobin <7.0 g/dL
    3. platelet count <50,000 cells/µL
    4. AST and/or ALT ≥5xULN OR ALT ≥3xULN and bilirubin ≥1.5xULN (with >35% direct bilirubin)
  2. Change in antiretroviral therapy within 12 weeks prior to randomisation
  3. Prior exposure to HIV protease inhibitors and/or HIV integrase inhibitors
  4. Patients with chronic viral hepatitis B infection defined by positive serum hepatitis B surface antigen
  5. Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy (INR >2.3), hypoalbuminemia (serum albumin <2.8g/dL), esophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  6. Anticipated need for Hepatitis C virus (HCV) therapy with interferon during the study
  7. Subject has creatinine clearance of <50 mL/min via CKD-EPI equation
  8. Current use of rifabutin or rifampicin
  9. Use of any contraindicated medications (as specified by product information sheets)
  10. Intercurrent illness requiring hospitalization
  11. An active opportunistic disease not under adequate control in the opinion of the investigator
  12. Pregnant or nursing mothers
  13. Patients with current alcohol or illicit substance use that in the opinion of the investigator might adversely affect participation in the study
  14. Patients deemed unlikely by the investigator to be able to remain in follow-up for the protocol-defined period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03017872

Contact: Simone S Jacoby +61 2 9385 0900 ext 50919

Hospital G de Agudos JM Ramos Mejia Not yet recruiting
Buenos Aires, Ciudad De Buenos Aires, Argentina, C1221ADC
Contact: Marcelo Losso    5411 4127 0276   
Contact: Guillermo Viloria    5411 4931 5252   
Principal Investigator: Marcelo Losso, M.D.         
Hospital Nacional Prof Alejandro Posadas Not yet recruiting
El Palomar, Provincia De Buenos Aires, Argentina, 1684
Contact: Lucia Esther Daciuk, M.D.    54 11 1544962605   
Contact: Hector Laplume, M.D.    54 11 1560426461   
Principal Investigator: Lucia Esther Daciuk, M.D.         
Hospital Dr Diego Paroissien Not yet recruiting
Isidro Casanova, Provincia De Buenos Aires, Argentina, 1765
Contact: Eduardo Warley    5411 1541 897 181   
Contact: Maria Ines Vieni    5411 1136 877 377 ext 3340   
Principal Investigator: Eduardo Warley, M.D.         
CAICI Not yet recruiting
Rosario, Provincia De Santa Fe, Argentina, S2000PBJ
Contact: Sergio Lupo    54 9 341 515 7704   
Contact: Luciana Peroni    54 341 424 8045   
Principal Investigator: Sergio Lupo, M.D.         
Hospital Interzonal de Agudos San Juan de Dios Not yet recruiting
La Plata, Argentina, 1900
Contact: Martha Michaan    +54 9221 5765 131   
Principal Investigator: Martha Michaan, M.D.         
Hospital San Borja-Arriaran Not yet recruiting
Santiago, Chile, 8360159
Contact: Marcelo Wolff    562- 555 6206   
Contact: Gladys Allendes    562-555-6206   
Principal Investigator: Marcelo Wolff, MD         
ASISTENCIA Cientifica De Alta Complejidad S.A.S. Not yet recruiting
Bogota, Colombia, 110010
Contact: Otto Sussmann    57-1- 5107600 ext 104   
Contact: Ana Julia Rojas    57-1-5107600 ext 128   
Principal Investigator: Otto Sussmann, M.D.         
YRG Care Not yet recruiting
Chennai, Tamil Nadu, India, 600113
Contact: Nagalingeswaran Kumarasamy    91 917 691 2007   
Contact: Faith Beulah    91 44 39106811   
Principal Investigator: Nagalingeswaran Kumarasamy, MD         
University of Malaya Medical Centre Not yet recruiting
Kuala Lumpur, Malaysia, 59100
Contact: Raja Iskandar Shah Raja Azwa    603-79493834   
Contact: Margaret Tan    603-79492622   
Principal Investigator: Raja Iskandar Shah Raja Azwa, MBChB, MRCP         
Morales Vargas Centro de Investigacion SC Not yet recruiting
León, Guanajuato, Mexico, 37000
Contact: Juan Luis Mosqueda Gomez    +52 (477) 1310037   
Contact: Jorge Morales Vargas    +52 (477) 7160714   
Hospital Civil de Guadalajara Not yet recruiting
Guadalajara, Jalisco, Mexico, 44280
Contact: Jaime Andrade-Villanueva   
Contact: Angeles González-Hernández    5233 3614 7586   
Principal Investigator: Jaime Andrade-Villanueva, M.D.         
Instituto Nacional de Ciencias Medicas y Nutriciòn Salvador Zubiran Not yet recruiting
Mexico City, Mexico, 14080
Contact: Juan Sierra Madero    52 5556559675   
Contact: Izchel Loyo   
Principal Investigator: Juan Sierra Madero, M.D.         
South Africa
Desmond Tutu HIV Foundation Recruiting
Cape Town, South Africa, 7925
Contact: Richard Kaplan   
Contact: Christie Heiberg    27 21 406 3621   
Principal Investigator: Richard Kaplan, M.D.         
Clinical HIV Research Unit (CHRU), Wits Health Consotium (Pty) Ltd Recruiting
Johannesburg, South Africa, 2041
Contact: Noluthando Mwelase   
Contact: Pauline Vunandala    27 11 276 8800   
Principal Investigator: Noluthando Mwelase, MBCHB         
Perinatal HIV Research Unit (PHRU), Chris Hani Baragwanath Hospital Recruiting
Soweto, South Africa, 1864
Contact: Lerato Mohapi   
Contact: Debra Peters    27 11 989 9700   
Principal Investigator: Lerato Mohapi, BSc, MBBCh         
HIV-NAT (The HIV Netherlands Australia Thailand Research Collaboration), Thai Red Cross AIDS Research Centre Recruiting
Bangkok, Thailand, 10330
Contact: Anchalee Avihingsanon    +662 652 3040 ext 107   
Contact: Kanitta Pussadee    +662 652 3040 ext 202   
Principal Investigator: Anchalee Avihingsanon, M.D.         
Chiangrai Prachanukroh Hospital Not yet recruiting
Chiang Rai, Thailand, 57000
Contact: Pacharee Kantipong    66818859195   
Contact: Supawadee Pongprapass    66819616900   
Principal Investigator: Pacharee Kantipong, M.D.         
Srinagarind Hospital, Khon Kaen University Not yet recruiting
Khon Kaen, Thailand, 40002
Contact: Ploenchan Chetchotisakd    6643363168   
Contact: Anchalee Tiyabut    6643363169   
Principal Investigator: Ploenchan Chetchotisakd, M.D.         
Bamrasnaradura Infectious Diseases Institute Not yet recruiting
Nonthaburi, Thailand, 11000
Contact: Weerawat Manosuthi   
Contact: Supeda Thongyen    6625903631   
Principal Investigator: Weerawat Manosuthi, M.D.         
University of Zimbabwe Clinical Research Centre Recruiting
Harare, Zimbabwe, +263
Contact: James G Hakim    263 772225489   
Contact: Shepherd Mudzingwa    263 4 701717   
Principal Investigator: James G Hakim, M.D.         
Sponsors and Collaborators
Kirby Institute
National Health and Medical Research Council, Australia
ViiV Healthcare
Janssen Pharmaceutica
Study Director: David A Cooper Kirby Institute

Responsible Party: Kirby Institute Identifier: NCT03017872     History of Changes
Other Study ID Numbers: D2EFT
First Posted: January 11, 2017    Key Record Dates
Last Update Posted: January 12, 2018
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Kirby Institute:
HIV, second-line

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
HIV Integrase Inhibitors
Integrase Inhibitors